The evolving medicines model
‘The very factors that drive the success of the generic market in the UK may be under threat’
Future of Pharmaceuticals 2019
It takes an average of 10-15 years to get a drug to market, but how will artificial intelligence make a difference in the early development stages of drugs? Our Future of Pharmaceuticals special report, published in The Times, explores how the industry is moving to be part of open, learning communities where collaboration is at the forefront. It examines why pharmaceuticals is lagging behind in exploiting technological possibilities and whether we should redefine ageing as a disease. It looks at antimicrobial resistance and what antibiotics are really worth. Also featured is an infographic analysing the global rise of generic drugs.
Please register to download
Please register to download this report. Registration is 100% free and provides access to all the latest insight and analysis shaping business today.
In association with
In this report
Sponsored content
-
Drug development goes digital
Strategic use of patient data is signalling a bright future for drug development in the face of unprecedented global healthcare challenges
-
Big data can help rescue healthcare
Innovative use of transformative big data can bring medicines to those in need, improve healthcare systems and empower patients
-
Tackling the next frontier of liver disease
An innovative pharma company has set its sights on treating non-viral liver diseases
-
Q&A: Connecting the dots along the pharma value chain
Industry leaders hold the “magic wand” to empower their talent to supercharge the potential of a patient-centric pharma value chain, says Louis Hendriks, founder and initiator of Global Value Web
-
Acino and Quay steer new course for contract development and manufacturing
As the era of blockbuster drugs comes to an end, pharma is moving towards drugs that are increasingly complex and made for small patient populations, creating opportunities and challenges for contract development and manufacturing organisations (CDMOs)
-
Future of Data 2021
They say that data is the “new oil” but companies are going to have to make sure they are drilling for it responsibly, or risk damaging repercussions. Our Future of Data report explores the opportunity for the UK to craft its own data strategy post Brexit, the importance of trust and transparency, the power of decision intelligence and whether companies really need a chief data officer
-
Customer Experience & Loyalty 2021
From shopping and leisure to workplace interaction and life admin, daily activities are becoming increasingly digitised. Businesses must understand the behaviour and preferences of their customers, as well as the strategies available for developing deeper engagement in order to ultimately build customer loyalty.
-
Future of Infrastructure 2021
Public spending on infrastructure is on the rise as governments strive to rebuild economies after Covid-19, but the pressure is growing to invest only in the greenest of projects. Our Future of Infrastructure report explores how infrastructure is under threat from climate risks and cyberthreats, the high cost of going low carbon and the UK’s e-mobility conundrum
-
Future CIO 2021
The CIO is becoming an increasingly important member of the boardroom as digital transformation and the pandemic raise the technology stakes for business. So how is the role adapting and how are companies nurturing the next-generation of IT leaders?